JPS61129124A - 抗腫瘍剤 - Google Patents
抗腫瘍剤Info
- Publication number
- JPS61129124A JPS61129124A JP25128684A JP25128684A JPS61129124A JP S61129124 A JPS61129124 A JP S61129124A JP 25128684 A JP25128684 A JP 25128684A JP 25128684 A JP25128684 A JP 25128684A JP S61129124 A JPS61129124 A JP S61129124A
- Authority
- JP
- Japan
- Prior art keywords
- antitumor agent
- formula
- tumor
- compound
- active ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002246 antineoplastic agent Substances 0.000 title claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 10
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- 239000000126 substance Substances 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 abstract description 7
- HNNIWKQLJSNAEQ-UHFFFAOYSA-N Benzydamine hydrochloride Chemical compound Cl.C12=CC=CC=C2C(OCCCN(C)C)=NN1CC1=CC=CC=C1 HNNIWKQLJSNAEQ-UHFFFAOYSA-N 0.000 abstract description 4
- 241001465754 Metazoa Species 0.000 abstract description 4
- 229960001689 benzydamine hydrochloride Drugs 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 3
- 125000000217 alkyl group Chemical group 0.000 abstract description 2
- 229910052736 halogen Inorganic materials 0.000 abstract description 2
- 150000002367 halogens Chemical class 0.000 abstract description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract description 2
- 238000007911 parenteral administration Methods 0.000 abstract description 2
- 210000004881 tumor cell Anatomy 0.000 abstract description 2
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract 1
- CNBGNNVCVSKAQZ-UHFFFAOYSA-N benzydamine Chemical class C12=CC=CC=C2C(OCCCN(C)C)=NN1CC1=CC=CC=C1 CNBGNNVCVSKAQZ-UHFFFAOYSA-N 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP25128684A JPS61129124A (ja) | 1984-11-28 | 1984-11-28 | 抗腫瘍剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP25128684A JPS61129124A (ja) | 1984-11-28 | 1984-11-28 | 抗腫瘍剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS61129124A true JPS61129124A (ja) | 1986-06-17 |
| JPH0559892B2 JPH0559892B2 (enrdf_load_stackoverflow) | 1993-09-01 |
Family
ID=17220542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP25128684A Granted JPS61129124A (ja) | 1984-11-28 | 1984-11-28 | 抗腫瘍剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS61129124A (enrdf_load_stackoverflow) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000027394A1 (en) * | 1998-11-05 | 2000-05-18 | University College London | Activators of soluble guanylate cyclase |
| GB2516436A (en) * | 2013-07-20 | 2015-01-28 | Pornthip Lattmann | Benzydamine, an anti-neoplastic agent, acting as cholecystokinin antagonist Gl and brain cancers |
| CN107873024A (zh) * | 2015-02-09 | 2018-04-03 | 塞尔利克斯生物私人有限公司 | 用于治疗粘膜炎的组合物和方法 |
-
1984
- 1984-11-28 JP JP25128684A patent/JPS61129124A/ja active Granted
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000027394A1 (en) * | 1998-11-05 | 2000-05-18 | University College London | Activators of soluble guanylate cyclase |
| GB2516436A (en) * | 2013-07-20 | 2015-01-28 | Pornthip Lattmann | Benzydamine, an anti-neoplastic agent, acting as cholecystokinin antagonist Gl and brain cancers |
| CN107873024A (zh) * | 2015-02-09 | 2018-04-03 | 塞尔利克斯生物私人有限公司 | 用于治疗粘膜炎的组合物和方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0559892B2 (enrdf_load_stackoverflow) | 1993-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100424503B1 (ko) | 암전이억제제 | |
| JPH0430924B2 (enrdf_load_stackoverflow) | ||
| JP2002534477A (ja) | メラガトランの新規使用 | |
| WO2002085117A1 (en) | Methods and compositions for preventing and treating septic shock and endotoxemia | |
| JPS61129124A (ja) | 抗腫瘍剤 | |
| JPS61106521A (ja) | 血管増殖抑制剤 | |
| EP0617959A1 (en) | Pharmaceutical for the treatment of skin disorders | |
| JPH07277964A (ja) | 抗腫瘍剤 | |
| EP0650723A2 (en) | Novel pharmaceutical use of forskolin derivatives | |
| HUP0203790A2 (hu) | (6-Metoxi-2-naftil)-ecetsav prodrugokat tartalmazó gyógyszerkészítmények alkalmazása gyulladás kezelésére | |
| EP0005074A1 (en) | A material and composition for reducing blood pressure | |
| JPS61129126A (ja) | 抗腫瘍剤 | |
| JPH03502802A (ja) | 抗嘔吐性エルゴリン誘導体 | |
| JPS61129128A (ja) | 抗腫瘍剤 | |
| JPS61129121A (ja) | 抗腫瘍剤 | |
| JPS61130222A (ja) | 抗腫瘍剤 | |
| JPS61130224A (ja) | 抗腫瘍剤 | |
| JPS61130221A (ja) | 抗腫瘍剤 | |
| JPS61130218A (ja) | 抗腫瘍剤 | |
| JPH0528690B2 (enrdf_load_stackoverflow) | ||
| JPS61130217A (ja) | 酢酸誘導体を含有する抗腫瘍剤 | |
| JPS61129125A (ja) | 抗腫瘍剤 | |
| JP2843944B2 (ja) | 利胆剤 | |
| JPH1160483A (ja) | Ｔｎｆ産生阻害剤 | |
| JPS61129131A (ja) | サリチル酸誘導体よりなる抗腫瘍剤 |